NCT06973720View on ClinicalTrials.gov

A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

October 31, 2026

Conditions
ObesityOverweight or Obesity
Interventions
DRUG

MET097

For subcutaneous administration.

DRUG

Placebo

Sterile 0.9% (w/v) saline for subcutaneous administration.

Trial Locations (5)

30030

Research Site 097203-001002, Decatur

31405

Research Site 097203-001005, Savannah

33024

Research Site 097203-001001, Hollywood

33613

Research Site 097203-001003, Tampa

08053

Research Site 097203-001004, Marlton

Sponsors

Lead Sponsor

Metsera
All Listed Sponsors
lead

Metsera

INDUSTRY

NCT06973720 - A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight | Biotech Hunter | Biotech Hunter